| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1a6dc3c7ffbcbd471cdd79d75d4b955 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2020-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_748a4458fbb93e0ae3c75800c1fa5404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67b0a91e8d665c0b3a9eb51d6fe27212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6a92af7b6cde32998516c27237e44e |
| publicationDate |
2022-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4017968-A1 |
| titleOfInvention |
T cell production from rag inactivated ipscs |
| abstract |
This invention relates to the differentiation of recombination activating gene (RAG) inactivated progenitor cells into T cells through the expression of an exogenous T Cell Receptor (TCR). A population of T cells may be produced by a method that comprises (i) differentiating a population of RAG inactivated induced pluripotent stem cells (IPSCs) into mesoderm cells, (ii) differentiating the mesoderm cells (MCs) to produce a population of haemogenic endothelial cells (HECs), (iii) differentiating the HECs into a population of haematopoietic progenitor cells (HPCs), (iv) differentiating the population of HECs into progenitor T cells; and (v) maturing the progenitor T cells to produce a population of double positive CD4+ CD8+ T cells. The method may further comprise introducing a heterologous nucleic acid encoding an antigen receptor, such as a T Cell Receptor (TCR) or chimeric antigen receptor (CAR), into one of the RAG inactivated (a) IPSCs (b) MCs (c) HECs (d) HPCs or (e) the progenitor T cells. This may be useful for example in the production of T cells for immunotherapy. |
| priorityDate |
2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |